EP1467975A1 - Alkyles uraciles substitues et leur utilisation - Google Patents

Alkyles uraciles substitues et leur utilisation

Info

Publication number
EP1467975A1
EP1467975A1 EP03704354A EP03704354A EP1467975A1 EP 1467975 A1 EP1467975 A1 EP 1467975A1 EP 03704354 A EP03704354 A EP 03704354A EP 03704354 A EP03704354 A EP 03704354A EP 1467975 A1 EP1467975 A1 EP 1467975A1
Authority
EP
European Patent Office
Prior art keywords
compounds
formula
substituted
amino
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03704354A
Other languages
German (de)
English (en)
Inventor
Barbara Albrecht
Michael Gerisch
Michael Härter
Thomas Krahn
Felix Oehme
Karl-Heinz Schlemmer
Henning Steinhagen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of EP1467975A1 publication Critical patent/EP1467975A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to new chemical compounds, a process for their preparation and their use as medicaments, in particular for the prophylaxis and / or treatment of ischemia and reperfusion damage.
  • PARS poly (ADP-ribose) synthetase
  • NMDA N-methyl-D-aspartate
  • NO-induced neurotoxicity NMDA
  • cerebral ischemia Endres et al., J. Cereb. Blood Flow Metabol., 17, 1143-1151 (1997)
  • traumatic brain injuries Wallis et al., Brain Res., 710, 169-177 (1996)
  • ischemia / re-perfusion damage in the heart and skeletal muscle ischemia / re-perfusion damage in the heart and skeletal muscle
  • PARS is activated, an enzyme that polymeric ADP-ribose units from nicotinamide adenosine
  • Dinucleotide (NAD + ) builds up as a substrate.
  • the polymeric ADP-ribose units formed are linked both to PARS itself and to other proteins, for example histones, topoisomerases and polymerases.
  • PARS knock-out mice that are healthy and capable of reproduction are essentially protected against reperfusion damage.
  • the infiltration of neutrophils is reduced by 50% and the structure of the myocardial tissue is preserved during the reperfusion phase.
  • Low-molecular PARS inhibitors such as 3-aminobenzamide and 1,5-dihydroxyisoquinoline protect the tissues from ischemia and reperfusion damage in the heart and brain from necrotic cell death (reduction of the infarct size by 30 to 48%) and a delay in myocardial and neuronal dysfunction.
  • 3-aminobenzamide is a non-specific PARS inhibitor which also inhibits cytochrome P 450 (Eriksson et al., Toxicology and applied Pharmacology, 136, 324-331 (1996)); 5-Iodo-6-amino-1,2-benzopyrone, on the other hand, shows strong side effects (Szabo and Dawson, Trends in Pharmacol. Sciences, 19, 287-298 (1998)).
  • most inhibitors are not very potent and therefore only show an effect in animals at a relatively high dosage (Thiemermann et al., Proc. Natl. Acad. Sei., 94, 679-683 (1997)).
  • JP-A-03264579 and Chem. Pharm. Bull. 38 (10), 2726-2732 (1990) describe bicyclic 2,4- (1H, 3H) -pyrimidinediones as 5-HT 2 antagonists for the treatment of cardiovascular diseases, depression and other mental illnesses.
  • US 5,859,014 discloses tetrahydroquinazolinedione derivatives as otradrenergic
  • Receptor antagonists used to treat prostate hypertrophy WO-A-00/42025 describes dihydropyrimidinones as PARS inhibitors.
  • DE-A-1959705 and DE-A-2126148 list uracil derivatives for the production of crop protection agents.
  • DE-A-2142317 names uracil derivatives with hypnotic properties.
  • various bridged uracils are used as nucleoside
  • the compounds according to the invention act here as inhibitors of the poly (ADP-)
  • the present invention relates to compounds of the formula (I)
  • A means -CH 2 -, -O- or -S-,
  • R 1 is hydrogen or alkoxycarbonyl
  • R 2 is aryl or heteroaryl, which in turn is up to three times, independently of one another, selected by substituents from the group of nitro, halogen, cyano, aryl, hetaryl, benzyl, alkyl, cycloalkyl, alkoxy, formyl, alkoxycarbonyl, trifluoromethyl, di- and Trifluoromethoxy, hydroxy, amino,
  • Alkylamino, aminosulfonyl, alkylsulfonylamino, arylsulfonylamino, hetarylsulfonylamino, -Y-OR and -Y-NR 3 R 4 can be substituted
  • R 3 and R 4 are independently hydrogen, optionally by
  • R 3 and R 4 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocycle which may contain a further heteroatom N, O or S in the ring and which may be by amino, hydroxy, alkoxycarbonyl or alkyl which in turn can be substituted by hydroxy or amino, is substituted,
  • R 5 denotes hydrogen or alkyl, which in turn can be substituted by phenyl, 4-hydroxyphenyl, amino, hydroxy, carboxyl, guanidino, imidazolyl, indolyl, mercapto or methylthio,
  • R, 3 and R together represent propane-1,3-diyl or butane-1,4-diyl
  • X denotes alkanediyl, in which a methylene group can be replaced by an oxygen atom.
  • the compounds according to the invention can also be present in the form of their salts, solvates or solvates of the salts.
  • the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers).
  • the invention therefore relates to the enantiomers or diastereomers and their respective mixtures.
  • the stereoisomerically uniform constituents can be isolated in a known manner from such mixtures of enantiomers and / or diastereomers.
  • the invention also relates to tautomers of the compounds.
  • preferred salts are physiologically acceptable salts of the compounds according to the invention.
  • Physiologically acceptable salts of compounds (I) include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid,
  • Ehansulfonic acid toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • Physiologically acceptable salts of the compounds (I) also include salts more commonly
  • Bases such as, for example and preferably, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts, derived from ammonia or organic amines having 1 to 16 carbon atoms, for example and preferably ethylamine, diethylamine, triethylamine, Ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclo-hexylamine,
  • alkali metal salts for example sodium and potassium salts
  • alkaline earth metal salts for example calcium and magnesium salts
  • ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, for example and preferably ethylamine, diethylamine, triethylamine, Ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclo-hexylamine,
  • solvates are those forms of the compounds which are in the solid or liquid state by coordination with Solvent molecules form a complex. Hydrates are a special form of solvate, in which coordination takes place with water.
  • Alkyl per se and "alk” and “alkyl” in alkoxy, alkylamino, alkylsulfonylamino and alkoxycarbonyl stand for a linear or branched alkyl radical with generally 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms, for example and preferably for methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
  • Alkoxy is exemplary and preferably methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
  • Alkylamino represents an amino radical with one or two independently selected alkyl substituents, for example and preferably methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexylamino, NN-dimethylamino, N, N Diethylamino, N-ethyl-N-methylamino, N-methyl-jV-n-propylamino, N-isopropyl-Nn-propylamino, Nt-butyl-N-methylamino,
  • Alkylsulfonylamino is an example and preferably methylsulfonylamino, ethylsulfonylamino, n-propylsulfonylamino, isopropylsulfonylamino, tert-butylsulfonylamino, n-pentylsulfonylamino and n-hexylsulfonylamino.
  • Alkoxycarbonyl is exemplified and preferably methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl.
  • Alkanediyl stands for a straight-chain or branched alkanediyl radical with generally 1 to 6, preferably 1 to 4, carbon atoms, for example and preferably for methylene, ethane-1,2-diyl, propane-1,2-diyl, propane-1,3- diyl, propane-2,2-diyl, butane-1,3-diyl, butane-1,4-diyl, butane-2,4-diyl, pentane-2,4-diyl, 2-methylpentane-2, 4-diyl.
  • a methylene group of the alkanediyl radical is optionally replaced by an oxygen atom
  • the following may be mentioned, for example and preferably: 3-oxa-butane-1,4-diyl, 4-oxa-butane-1,4-diyl, 3-oxapentane l, 5-diyl, 4-oxapentane-l, 5-diyl, 4-oxa-hexane-1,6-diyl.
  • Alkenyl represents a straight-chain or branched alkenyl radical with generally 2 to 6, preferably 2 to 4, particularly preferably 2 or 3 carbon atoms, for example and preferably vinyl, allyl, n-prop-1-en-l-yl, n- but-2-en-l-yl.
  • Cycloalkyl stands for a cycloalkyl group with generally 3 to 8, preferably 5 to 7 carbon atoms, for example and preferably for cyclopropyl, cyclobutyl,
  • Aryl per se and "aryl” in arylsulfonylamino stands for a mono-, bi- or tricyclic aromatic, carbocyclic radical with generally 6 to 14 carbon atoms; exemplary and preferably for phenyl, naphthyl and phenanthrenyl.
  • Arylsulfonylamino is exemplary and preferably phenylsulfonylamino, naphthylsulfonylamino and phenantlirenylsulfonylamino.
  • Heteroaryl per se and "hetaryl” in hetarylsulfonylamino stands for an aromatic, optionally benzo-fused radical with generally 5 or 6 ring atoms and up to 3 heteroatoms from the series S, O and N, by way of example and preferably for thienyl, furyl, pyrrolyl, thiazolyl , Oxazolyl, pyrazolyl, imidazolyl, isoxazolyl, isothiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl.
  • Hetarylsulfonylamino is exemplary and preferably pyridylsulfonylamino, thienylsulfonylamino and pyrazolylsul
  • Halogen stands for fluorine, chlorine, bromine and iodine.
  • A means -CH 2 - or -S-,
  • R 1 represents hydrogen
  • R 2 is phenyl, pyridyl, pyrazolyl or imidazolyl, which in turn is up to three times, independently of one another, selected from the group of nitro, halogen, phenyl, benzyl, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) Alkoxy, formyl, (C] -C 4 ) -alkoxycarbonyl, amino, hydroxy, aminosulfonyl and -Y-NR 3 R 4 can be substituted,
  • R 3 and R 4 are independently hydrogen, optionally substituted by hydroxy or amino (C] -C 4 ) - alkyl, (C 2 -C 4 ) alkenyl or (-C-C 4 ) - alkoxycarbonyl or
  • R 3 and R 4 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocycle which may contain a further heteroatom N or O in the ring and which may be substituted by amino, hydroxy, (-C-C 4 ) - Alkoxycarbonyl or (-C-C 4 ) alkyl, which in turn can be substituted by hydroxy or amino, is substituted,
  • X denotes (C i -C 4 ) alkanediyl.
  • a -S- means
  • R 1 represents hydrogen
  • R 2 denotes phenyl or imidazolyl, which in turn can be substituted up to three times, independently of one another, by substituents selected from the group consisting of nitro, fluorine, chlorine, bromine, methyl, ethyl, isopropyl, methoxycarbonyl and -Y-NR 3 R 4 ,
  • R and R together with the nitrogen atom to which they are attached, pyrrolidin-1-yl, piperidin-1-yl, piperazin-1-yl, 4-methylpiperazin-l-yl, 4- (2-hydroxyethyl) piperazin-l -yl or morpholin-4-yl mean
  • X represents ethane-1,2-diyl, propane-1,3-diyl or butane-1,4-diyl.
  • the present invention also relates to a method for producing the
  • A, X and R have the meaning given above and R 1 represents hydrogen
  • R 1 has the meaning given above but is not hydrogen and Z represents a leaving group
  • the compounds of formula (I) obtained in this way can then optionally be converted by reaction e.g. be converted into the corresponding salts with an acid.
  • R 2 represents heteroaryl which is linked to the hydrogen atom via a nitrogen atom
  • X has the meaning given above and Z 'represents a leaving group
  • Suitable solvents for the processes described above are organic solvents which are inert under the reaction conditions or water. These include halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, 1, 2-dichloroethane, trichloroethane, tetrachloroethane, 1,2-dichloroethylene or trichlorethylene, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol, benzol, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene, toluene,
  • the reactions can be carried out at normal, elevated or reduced pressure (for example in the range from 0.5 to 5 bar). Generally one works at
  • bases are suitable as bases.
  • bases preferably include alkali and alkaline earth metal hydroxides such as lithium, sodium or potassium hydroxide or alkali and alkaline earth metal carbonates such as sodium or potassium carbonate or sodium or potassium methoxide or sodium or potassium ethoxide or potassium tert-butoxide or amides such as sodium amide, lithium bis ( trimethylsilyl) amide or lithium diisopropylamide or amines such as triethylamine, diisopropylethylamine, diisopropylamine, N-methylmorpholine, 4-dimethylamino-pyridine or pyridine.
  • alkali and alkaline earth metal hydroxides such as lithium, sodium or potassium hydroxide or alkali and alkaline earth metal carbonates such as sodium or potassium carbonate or sodium or potassium methoxide or sodium or potassium ethoxide or potassium tert-butoxide or amides
  • amides such as sodium amide, lithium bis ( trimethylsily
  • reaction step (II) + (III) -> (IV) is preferably carried out in toluene as the solvent.
  • the temperature range for this reaction is in particular between 80 ° C and 120 ° C.
  • the reaction can optionally be accelerated by adding catalytic amounts of acid, preferably organic sulfonic acid, in particular camphorsulfonic acid.
  • reaction of compounds (IV) with chlorocarbonyl isocyanate to give compounds (Ia) is preferably carried out in toluene as the solvent.
  • the addition of chlorocarbonyl isocyanate is preferably carried out at room temperature, the other
  • the reaction then takes place in particular in a temperature range between 80 ° C and 120 ° C.
  • the leaving group Z for compounds of the formula (V) is, for example: halogen or 1-imidazolyl. Chlorine is preferred.
  • the reaction (VI) + (VII) -> (VIII) is preferably carried out in dimethylformarnide as solvent with potassium carbonate as base. The preferred temperature range for this reaction is between 20 ° C and 130 ° C. Halogen, mesylate, tosylate or, for example, can be used as leaving group Z 'in compounds of the formula (VII)
  • Triflate can be used, bromine is preferred.
  • the compounds of the formula (VIII) obtained in the above reaction are preferably reacted further in ethanol as a solvent with aqueous hydrazine hydrate solution in a temperature range from 50 ° C. to 80 ° C., the phthalimide
  • the amines of the formula (III) can be obtained in the form of their salts.
  • the compounds of formula (I) surprisingly show an unforeseeable, valuable pharmacological and pharmacokinetic spectrum of action and are therefore particularly useful for the prophylaxis and / or treatment of diseases
  • the compounds according to the invention can be used preferably for the prophylaxis and / or treatment of ischemia and reperfusion damage
  • Hearts (after acute infarction), in the brain (after a stroke) or skeletal muscle, cardiovascular diseases such as unstable angina pectoris and arteriosclerosis, neuronal and neurodegenerative diseases such as epilepsy, chronic pain, Alzheimer's disease and Parkinson's disease, traumatic brain injuries, septic shock and arthritis Diabetes chronic colitis, sudden hearing loss, inflammatory diseases of the lungs such as asthma and chronic bronchitis and cancer.
  • cardiovascular diseases such as unstable angina pectoris and arteriosclerosis
  • neuronal and neurodegenerative diseases such as epilepsy, chronic pain, Alzheimer's disease and Parkinson's disease, traumatic brain injuries, septic shock and arthritis Diabetes chronic colitis, sudden hearing loss, inflammatory diseases of the lungs such as asthma and chronic bronchitis and cancer.
  • the present invention further relates to medicaments which contain at least one compound according to the invention, preferably together with one or more pharmaceutically acceptable auxiliaries, and to their use for the purposes mentioned above.
  • the present invention further relates to a method for the prophylaxis and / or treatment of the aforementioned clinical pictures with the substances of
  • the compounds according to the invention can also be used in the treatment of acute myocardial infarction in combination with one or more of the following medicaments which belong to the standard therapy for acute myocardial infarction: calcium channel blockers (such as, for example, nifedipine, diltiazem, verapamil), nitrovasodilators (such as, for example, isosorbide dinitrate , Glycerol trinitrate, isosorbide-5-mono-nitrate, molsidomine), beta-blockers (such as metoprolol, atenolol, propranolol, solatol), platelet aggregation inhibitors (such as acetylsalicylic acid, triclopidine, clopidrogrel) (thrombolytics) such as thrombolytics eg streptokinase,reteplase, urokinase, anistreplase), anticoagulants
  • calcium channel blockers such as
  • the active substance can act systemically and / or locally.
  • it can be applied in a suitable manner, such as, for example, orally, parenterally, pulmonally, nasally, sub-lingually, lingually, buccally, rectally, transdermally, conjunctivally, otically or as an implant, for example in the form of an active ingredient-containing stent.
  • the active ingredient can be administered in suitable administration forms for these administration routes.
  • Known application forms which release the active ingredient quickly and / or modified such as e.g. Tablets (non-coated and coated tablets, e.g. tablets or film-coated tablets provided with enteric coatings), capsules, dragees, granules, pellets, powders, emulsions, suspensions, solutions and aerosols.
  • Tablets non-coated and coated tablets, e.g. tablets or film-coated tablets provided with enteric coatings
  • capsules dragees, granules, pellets, powders, emulsions, suspensions, solutions and aerosols.
  • Parenteral administration can be done by bypassing an absorption step (intravenously, intraarterially, intracardially, intraspinally or intralumbally) or by switching on absorption (intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
  • Suitable forms of application for parenteral administration include: Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates and sterile powders.
  • Inhaled drug forms e.g. powder inhalers, nebulizers
  • nasal drops / solutions, sprays e.g., aqueous suspensions (lotions, shake mixes), lipophilic suspensions, ointments, creams, milk, pastes, powder or implants.
  • the active compounds can be converted into the application forms mentioned in a manner known per se. This is done using pharmaceutically acceptable excipients.
  • pharmaceutically acceptable excipients include Carriers (e.g. microcrystalline cellulose), solvents (e.g. liquid polyethylene glycols), emulsifiers (e.g. sodium dodecyl sulfate), dispersants (e.g. polyvinylpyrrolidone), synthetic and natural biopolymers (e.g. albumin), stabilizers (e.g. antioxidants such as ascorbic acid), dyes (e.g. inorganic pigments such as iron oxides) ) or
  • Carriers e.g. microcrystalline cellulose
  • solvents e.g. liquid polyethylene glycols
  • emulsifiers e.g. sodium dodecyl sulfate
  • dispersants e.g. polyvinylpyrrolidone
  • synthetic and natural biopolymers e.g. albumin
  • stabilizers
  • the therapeutically active compounds should be present in the pharmaceutical preparations listed above in a concentration of approximately 0.1 to 99.5, preferably approximately 0.5 to 95% by weight of the total mixture, ie the active substance should be present in quantities that are sufficient to achieve the specified dosage range.
  • the active ingredient (s) according to the invention in total amounts of from about 0.01 to about 100, preferably 0.05 to 50 mg / kg of body weight per 24 hours , if necessary in the form of several single doses, to achieve the desired results.
  • a single dose contains the active ingredient (s) according to the invention preferably in amounts of about 0.01 to 50, in particular 0.1 to 10 mg / kg body weight.
  • the inhibition of the P ARS activity can be represented as a% value of the PARS inhibition when incubated with various substances or as the concentration at which 50% of the enzyme is inhibited, ie as an IC 50 value.
  • Tris-HCl and MgCl 2 are dissolved in water, DTT is added from a 100 mM aqueous starting solution (stored at -20 ° C.) and the pH is adjusted to 7.4 with concentrated HC1.
  • DNA 1 mg / ml calf thymus DNA
  • Histones 10 mg / ml type IIA histones, calf thymus
  • NAD + Mix 2 mM NAD + in buffer
  • NAD + (Sigma) solutions are freshly prepared before each test. 3 ⁇ l of labeled [ 14 C] -NAD + (2.8 kBq, from Amersham) are added to 7 ⁇ l of cold NAD + solution in each case.
  • TCA Trichloroacetic acid
  • PARS Human PARS protein is expressed recombinantly in the Baculo virus system (Bac-To-Bac, Baculo virus expression system; Instruction Manual; Life Technologies) and purified. 500 ⁇ l aliquots are stored at -80 ° C.
  • the compounds to be tested are in a concentration of 10 mM in DMSO
  • the assay is carried out in deep 96-hole plates. 70 ⁇ l buffer, 10 ⁇ l DNA, 10 ⁇ l histones, 10 ⁇ l NAD + / [ 14 C] -NAD + are used per hole
  • DHCH 1,5-dihydroxyisoquinoline
  • MHEC5-T cells / hole (DSM ACC 336; German collection of microorganisms and cell cultures) are sown as a 4-fold determination on a 96-hole plate.
  • the cells are incubated with 3 mM aqueous H 2 O 2 solution and various concentrations of the substances in the presence of 6% by volume Alamar blue solution in the medium for 5 hours at 37 ° C. 10 ⁇ M 1,5-dihydroxyisoquinoline (DHCH) solution is used as reference substance.
  • DHCH 1,5-dihydroxyisoquinoline
  • The% value of cell protection is calculated as the difference between the living cells that are only with H 2 O 2 , and the cells that are with
  • H 2 O 2 and PARS inhibitor are treated. 10 ⁇ M DHCH is used as the internal standard and 100% protection is set. The values obtained for the other substances are related to this value.
  • EC 50 values indicate the concentration at which 50% of the maximum cell protection is reached, the maximum protection being set as 100% value by 10 ⁇ M DHCH.
  • DHCH has an EC 50 value of
  • isolated rat hearts are subjected to a 60-minute “low flow” phase to generate global ischemia and investigated the effect of the substances on the restoration of the left ventricular pressure (LVPmax) and the contraction force (dP / dt) during the reperfusion phase. 1,5-Dihydroxyisoquinoline is used as the control substance.
  • EDC N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride
  • Example 7 c) Instructions for Example 7 c) are obtained after the amine has been released and reacted with tetrahydrothiopyran-4-one (2.2 g, 18.97 mmol) and chlorocarbonyl isocyanate (1.67 ml, 20.69 mmol) a crude product which can be purified by preparative HPLC chromatography (column: Kromasil 100 C 18, 250 x 20 mm; eluent: methanol / 0.2% - aqueous trifluoroacetic acid; flow: 25 ml / min; UV detection at 274 nm). 125 mg (0.4 mmol, 2% of theory) of the title compound are obtained as the free base and 304 mg (0.7 mmol, 4% of theory) as the corresponding trifluoroacetate salt.
  • reaction mixture is hydrogenated overnight in a hydrostatic hydrogen atmosphere. Then it is filtered through Celite and washed with methanol. The solvent is removed in vacuo and the residue obtained by means of preparative HPLC (column: Kromasil 100 C 18.5 mm; 250 x 40 mm; Eluent: acetonitrile / water; Flow: 50 ml / min; UV detection at 254 nm) cleaned. 417 mg (1.37 mmol; 45% of theory) of the title compound are obtained as a yellow solid.
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows:
  • Example 1 100 mg of the compound from Example 1, 50 mg lactose (monohydrate), 50 mg corn starch (native), 10 mg polyvinylpyrolidone (PVP 25) (from BASF, Ludwigshafen, Germany) and 2 mg magnesium stearate.
  • the mixture of active ingredient, lactose and starch is granulated with a 5% solution (m / m) of the PVP in water.
  • the granules are dried with the magnesium stearate for 5 min. mixed.
  • This mixture is compressed with a conventional tablet press (tablet format see above).
  • a pressure force of 15 kN is used as a guideline for the pressing.
  • a single dose of 100 mg of the compound according to the invention corresponds to 10 ml of oral suspension.
  • Rhodigel is suspended in ethanol, the active ingredient is added to the suspension. The water is added with stirring. The swelling of the Rhodigel is stirred for about 6 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés de la formule (I), leur procédé de production et leur utilisation comme principes actifs médicamenteux destinés à la prévention et/ou au traitement de maladies.
EP03704354A 2002-01-15 2003-01-03 Alkyles uraciles substitues et leur utilisation Withdrawn EP1467975A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10201240A DE10201240A1 (de) 2002-01-15 2002-01-15 Substituierte Alkyluracile und ihre Verwendung
DE10201240 2002-01-15
PCT/EP2003/000027 WO2003059892A1 (fr) 2002-01-15 2003-01-03 Alkyles uraciles substitues et leur utilisation

Publications (1)

Publication Number Publication Date
EP1467975A1 true EP1467975A1 (fr) 2004-10-20

Family

ID=7712157

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03704354A Withdrawn EP1467975A1 (fr) 2002-01-15 2003-01-03 Alkyles uraciles substitues et leur utilisation

Country Status (6)

Country Link
US (1) US20050159431A1 (fr)
EP (1) EP1467975A1 (fr)
AU (1) AU2003206694A1 (fr)
CA (1) CA2473362A1 (fr)
DE (1) DE10201240A1 (fr)
WO (1) WO2003059892A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449766T1 (de) * 2002-10-23 2009-12-15 Janssen Pharmaceutica Nv Piperazinyl- und diazapanylbenzamide und- benzothioamide
EP1741709A1 (fr) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Amides heterocycliques substitués contenant un linker saturé, et leur utilisation comme agent pharmaceutique
CA2672661C (fr) * 2006-12-14 2015-04-28 Janssen Pharmaceutica N.V. Procede de preparation de derives de piperazinyle et diazepanyle benzamide
PL2239257T3 (pl) * 2008-01-30 2012-10-31 Shin Poong Pharmaceutical Co Ltd Nowe pochodne chinazolino-2,4-dionu oraz zawierające je farmaceutyczne kompozycje do profilaktyki i leczenia chorób nerwów czaszkowych
CN103443085B (zh) 2011-03-14 2016-03-23 南京英派药业有限公司 喹唑啉二酮及其应用
TWI527800B (zh) 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
EP2731951B1 (fr) 2011-07-13 2015-08-19 Novartis AG Composés de 4-oxo-3,5,7,8-tétrahydro-4h-pyrano{4,3-d}pyriminidinyle utilisables à titre d'inhibiteurs de tankyrases
JP5957077B2 (ja) 2011-07-13 2016-07-27 ノバルティス アーゲー タンキラーゼ阻害剤として使用するための４−ピペリジニル化合物
EP2731942B1 (fr) 2011-07-13 2015-09-23 Novartis AG Nouveaux composés 2-piperidin-1-yl-acetamide utilisables en tant qu'inhibiteurs de tankyrase
EP2773623B1 (fr) * 2011-11-01 2020-04-29 Impact Therapeutics, Inc. 1-(arylméthyl)-5,6,7,8-tétrahydroquinazoline-2,4-diones et leurs analogues et leur utilisation
EP3332645A1 (fr) 2016-12-12 2018-06-13 Bayer Cropscience AG Utilisation de pyrimidinedione ou ses sels respectifs en tant qu'agent contre l'agression abiotique des plantes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2166975C (fr) * 1993-07-16 2005-04-05 Mark G. Bock Derives de la benzoxazinone et de la benzopyrimidinone, antagonistes des recepteurs de l'oxytocine et de la vasopressine
DE4341665A1 (de) * 1993-12-07 1995-06-08 Basf Ag Bicyclen-Derivate, ihre Herstellung und Verwendung
US6048863A (en) * 1994-04-19 2000-04-11 Takeda Chemical Industries, Ltd. Condensed-ring thiophene derivatives and thienopyrimidine derivatives, their production and use
ATE225173T1 (de) * 1995-08-02 2002-10-15 Univ Newcastle Ventures Ltd Benzimidazol verbindungen
US6166019A (en) * 1998-07-16 2000-12-26 Abbott Laboratories Piperazinyl pyrimidine dione compounds selective for adrenoceptors
DE10034801A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Substituierte Amidoalkyl-uracile und ihre Verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03059892A1 *

Also Published As

Publication number Publication date
WO2003059892A1 (fr) 2003-07-24
US20050159431A1 (en) 2005-07-21
DE10201240A1 (de) 2003-07-24
AU2003206694A1 (en) 2003-07-30
CA2473362A1 (fr) 2003-07-24

Similar Documents

Publication Publication Date Title
DE69917296T2 (de) Neue substituierte triazolverbindungen
DE60305484T2 (de) Verbindungen und deren verwendung als 5-ht inhibitoren
EP1425283B1 (fr) Nouvelles 4-aminofuropyrimidines et leur utilisation
DE3717561A1 (de) Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP2002507611A (ja) イミダゾロン食欲抑制薬：ｉｉ．フェニル誘導体
DE10230605A1 (de) Substituierte Imidazotriazine
WO2004005291A1 (fr) Imidazotriazines heterocycliquement substituees
DE10312969A1 (de) Benzofuro-1,4-diazepin-2-on-Derivate
EP1467975A1 (fr) Alkyles uraciles substitues et leur utilisation
WO2005028451A1 (fr) Tetrahydrochinoxalines et leur utilisation comme agonistes du recepteur a l'acetylcholine m2
EP1025100A1 (fr) Derives de tetrahydropyridopyrimidinone substitues en position 3, leur production et leur utilisation
EP1625129B1 (fr) Dihydroquinazolines substituees par heterocyclyle et leur utilisation comme antiviraux
DD256132A5 (de) Verfahren zur herstellung von neuen cyclischen aminderivaten
WO2002040455A1 (fr) Amidoalkyl-uraciles substitues et leur utilisation en tant qu'inhibiteurs de la poly(adp-ribose)-synthetase (pars)
US6649618B2 (en) Substituted amidoalkyl-uracils and their use
DE19746612A1 (de) 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung
EP1732901B1 (fr) Composes imidazole a substitution 4-aminocarbonylamino a activite antivirale
DE102004022672A1 (de) Substituierte Azachinazoline
EP1104419B1 (fr) Derives a substitution n d'azacycloheptane, preparation et utilisation desdits utilises
EP1476164B1 (fr) Quinoxalinones et leur utilisation notamment pour traiter des affections cardiovasculaires
WO2004058716A1 (fr) 4-aryl-pyridines servant d'antagonistes de kiss-1
EP1105388B1 (fr) Derives a substitution n d'azabicycloheptane, preparation et utilisation desdits derives
DE10203086A1 (de) 5-Ring Heterozyklen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040816

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060824